Eight Stocks Positioned for Short Sales – Oppenheimer Asset Management
Eli Lilly and Co (LLY.US) CEO: Its Alzheimer's drugs can play a "preventive" role.
Eli Lilly and Co's CEO told the United Kingdom Health Minister that their method of treating Alzheimer's disease can 'prevent' the disease.
Eli Lilly CEO Told UK Health Secretary Its Alzheimer's Treatment Could "Prevent" Disease: FT
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $225
Maintaining Hold on Biogen Amid Modest Growth and Cautious Outlook
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $285
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
Biogen Reinstated at Market Perform at Raymond James on Leqembi Disappointment
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Raymond James Downgrades Biogen(BIIB.US) to Hold Rating
Biogen Analyst Ratings
Raymond James Downgrades Biogen to Market Perform
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Announces Target Price $220
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW)
Biogen's Felzartamab Gets FDA Breakthrough Therapy Status in Kidney Transplant Rejection
Biogen's Stock Bounces After Treatment for Kidney-transplant Rejection Gets FDA Boost
Biogen Announces Felzartamab Received BTD From FDA
Express News | Biogen Inc - to Initiate Phase 3 Trials for Felzartamab in 2025
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study